Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Genetic dynamics and factors predictive of survival in relapsed AML

Alex Bataller • 15 Jun 2024
EHA 2024
Acute Myeloid Leukemia Leukemia

Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study investigating the genetic dynamics and factors predictive of survival in patients with acute myeloid leukemia (AML) at first relapse. Dr Bataller highlights that some mutations were more likely to persist at first relapse, and the choice of chemotherapy impacted the genetic dynamics of a patient. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Alex Bataller

The future of precision medicine in MDS: genomic profiling and venetoclax-based strategies
1:55
The future of precision medicine in MDS: genomic profiling and venetoclax-based strategies
Alex Bataller • 8 Jun 2026
Whole genome sequencing reveals clinically relevant alterations missed by standard testing in MDS
1:17
Whole genome sequencing reveals clinically relevant alterations missed by standard testing in MDS
Alex Bataller • 8 Jun 2026
HMA with or without venetoclax in treatment-naïve MDS with excess blasts: a retrospective analysis
1:13
HMA with or without venetoclax in treatment-naïve MDS with excess blasts: a retrospective analysis
Alex Bataller • 8 Jun 2026
Factors influencing the choice of intensive therapy in AML: age, performance status & genetics
1:02
Factors influencing the choice of intensive therapy in AML: age, performance status & genetics
Alex Bataller • 8 Dec 2025

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals